ESMO Asia 2025 | Current management strategies for gestational trophoblastic disease

Yes, because of my talk is only 20 minutes and the spectrum of the gestational trophoblastic disease is widely covered, the benign and malignant. I think the audience, most of them are medical oncologists. So I will focus on the cancer aspect and the medical treatment because this cancer can be cured with chemotherapy and also the innovation of the treatment like immunotherapy. So I will touch a little bit of the overview and for the benign aspect, I will go through it quickly and then focus on the malignant aspect and go through the chemotherapy regimen and new aspects of the treatment in experimental research treatment. The malignant form of the gestational trophoblastic disease, we call it gestational trophoblastic neoplasia, which has a spectrum in the clinical spectrum, we separate into low risk and high risk. For low risk, we treat with single-agent chemotherapy, which is very conventional chemotherapy like methotrexate and actinomycin-D. And for high-risk disease, we use combination chemotherapy regimens like EMA-CO and for the 5-FU-based in China. And the treatment has a very good effect. Overall treatment for the malignant is around 90 percent cure but it’s very toxic and also there’s another 10 percent with resistant or refractory disease; this group of patients we have to find a proper way of treatment which leads to the normal treatment like immunotherapy like pembrolizumab or bevacizumab.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.